A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus.
|
| Abstract |
The discovery of autoantibodies to ribosomal proteins (anti-RibP) dates back more than fifty years when antibodies to ribosomes were identified in systemic lupus erythematosus (SLE) sera. Over the years, anti-RibP autoantibodies have been the subject of extensive study and became known as a highly specific biomarker for the diagnosis of SLE and were associated with neuropsychiatric SLE (NPSLE), lupus nephritis (LN) and hepatitis (LH). As demonstrated by studies on cultured human cells and of murine models, there is evidence to suggest that anti-RibP may have a pathogenic role in LN and NPSLE. Despite a wealth of evidence, in comparison to other SLE autoantibodies such as anti-Sm and anti-dsDNA, anti-RibP has not been included in classification criteria for SLE. A significant challenge is the variability of assays used to detect anti-RibP, including the antigens and diagnostic platforms employed. This may account for the marked variation in frequencies (10-47%) in SLE and its association with clinical and demographic features reported in SLE cohorts. We performed a systematic literature review and meta-analysis to help clarify its prevalence, various clinical and serological associations in SLE based on the different RibP antigens and assay platforms used.
|
|---|---|
| Authors | May Y Choi, Rachael D FitzPatrick, Katherine Buhler, Michael Mahler, Marvin J Fritzler |
| Journal | Autoimmunity reviews (Autoimmun Rev) Vol. 19 Issue 3 Pg. 102463 (Mar 2020) ISSN: 1873-0183 [Electronic] Netherlands |
| PMID | 31927088 (Publication Type: Journal Article, Meta-Analysis, Systematic Review) |
| Copyright | Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!